Digestive Diseases and Sciences

, Volume 47, Issue 6, pp 1195–1205 | Cite as

Analysis of Sequence Configurations of the ISDR, PKR-Binding Domain, and V3 Region as Predictors of Response to Induction Interferon-α and Ribavirin Therapy in Chronic Hepatitis C Infection

  • Melissa D. Murphy
  • Hugo R. Rosen
  • Gail I. Marousek
  • Sunwen Chou


Interferon (IFN) and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection yields a sustained response rate of only ∼40%. Previous studies have linked IFN responsiveness to viral sequence variation in parts of the E2 and NS5A genes, but this remains controversial. We studied pretreatment sera from 28 subjects (23 with HCV genotype 1a) who received high-dose IFN induction followed by IFN–ribavirin combination therapy. Serum HCV sequences were amplified and compared from 14 responders with undetectable HCV RNA 24 weeks after therapy and 11 nonresponders (excluding three who dropped out of the study). Analysis included the E2 PKR eIF-2α phosphorylation homology domain (PePHD, codons 659–670), where the sequence was well conserved, and codons 2001–2420 of NS5A. In NS5A, the proposed PKR binding domain (codons 2209–2274), containing the putative IFN sensitivity determining region (ISDR, codons 2209–2248), showed too little variation among subjects to differentiate responders and nonresponders. NS5A codons 2356–2385 (which includes the V3 region) exhibited more variation. Here, six of 12 genotype 1a responders showed four or more amino acid changes from the prototype HCV-1 sequence, as compared with one of eight nonresponders, but this fell short of statistical significance (P = 0.16). NS5A sequences from posttreatment sera were examined in six nonresponders to look for selection of treatment-resistant viral subpopulations, but no consistent change was detected. In conclusion, our results indicate that the sequences of the ISDR, the PKR-binding domain, and the PePHD are unlikely to have predictive value for IFN treatment success in those infected with HCV genotype 1a. However, the finding of greater variability among treatment responders in the carboxy end of NS5A suggests that the V3 region merits further investigation.

interferon sensitivity determining region (ISDR) PKR binding domain V3 region PKR-eIF-2α phosphorylation homology domain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562, 1999PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus infection and HCV-related chronic disease. MMWR 47(NRR-19):1–39, 1998Google Scholar
  3. 3.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492, 1998PubMedGoogle Scholar
  4. 4.
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426–1432, 1998PubMedGoogle Scholar
  5. 5.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 96:224–230, 1995PubMedGoogle Scholar
  6. 6.
    Zeuzem S, Lee JH, Roth WK: Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25:740–744, 1997PubMedGoogle Scholar
  7. 7.
    Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR: Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 53:118–126, 1997PubMedGoogle Scholar
  8. 8.
    Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, Capron D, Capron JP, Lunel F, Stuyver L, Duverlie G: Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J. Hepatology 27:72–77, 1997Google Scholar
  9. 9.
    Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, Eb F, Penin F, Wychowski C: Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79:1373–1381, 1998PubMedGoogle Scholar
  10. 10.
    Rispeter K, Lu M, Zibert A, Wiese M, de Oliveira JM, Roggendorf M: The “interferon sensitivity determining region” of hepatitis C virus is a stable sequence element. J Hepatol 29:352–361, 1998PubMedGoogle Scholar
  11. 11.
    Odeberg J, Yun Z, Sonnerborg A, Weiland O, Lundeberg J: Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol 56:33–38, 1998PubMedGoogle Scholar
  12. 12.
    Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Loiacono O, Siciliane R, Levrero M, Raimondo G: Long-term response to interferon alpha is unrelated to “interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 30:1023–1027, 1999PubMedGoogle Scholar
  13. 13.
    Chung RT, Monto A, Dienstag JL, Kaplan LM: Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 58:353–358, 1999PubMedGoogle Scholar
  14. 14.
    Ibarrola N, Moreno-Monteagudo JA, Saiz M, Garcia-Monzon C, Sobrino F, Garcia-Buey L, Iacono O, Moreno-Otero R, Martínez-Salas E: Response to retreatment with interferonalpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence. Am J Gastroenterol 94:2487–2495, 1999PubMedGoogle Scholar
  15. 15.
    Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H: Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745–749, 1997PubMedGoogle Scholar
  16. 16.
    Murashima S, Ide T, Miyajima I, Kumashiro R, Ueno T, Sakisaka S, Sata M: Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Scand J Infect Dis 31:27–32, 1999PubMedGoogle Scholar
  17. 17.
    Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M: Number and position of mutations in the interferon sensitivity-determining region of the gene for non-structural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 183:1195–1203, 2001PubMedGoogle Scholar
  18. 18.
    Saiz JC, Lopez-Labrador FX, Ampurdanes S, Dopazo J, Forns X, Sanchez-Tapias JM, Rodes J: The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 177:839–847, 1998PubMedGoogle Scholar
  19. 19.
    Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, Zeuzem S: Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 30:1004–1013, 1999PubMedGoogle Scholar
  20. 20.
    Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217–227, 1997PubMedGoogle Scholar
  21. 21.
    Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG: Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation. Mol Cell Biol 18:5208–5218, 1998PubMedGoogle Scholar
  22. 22.
    Taylor RT, Shi ST, Romano PR, Barber GN, Lai MMC: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107–110, 1999PubMedGoogle Scholar
  23. 23.
    National Institutes of Health: Management of hepatitis C. NIH Consensus Statement Online 1997 Mar 24–26 Conf. 15(3):1–41Google Scholar
  24. 24.
    Anonymous: Interferon plus ribavirin for chronic hepatitis C. Med Lett 41(1054):June 4, 1999.Google Scholar
  25. 25.
    Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kumada H: Efficacy and changes of the nonstructural 5A gene by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV RNA. Intern Med 38:461–466, 1999PubMedGoogle Scholar
  26. 26.
    Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH: The epidemic behavior of the Hepatitis C virus. Science 292:2323–2325, 2001PubMedGoogle Scholar
  27. 27.
    Inchauspe G, Zebedee S, Lee D-H, Sugitani M, Nasoff M, Prince AM: Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates. Proc Natl Acad Sci USA 88:10292–10296, 1991PubMedGoogle Scholar
  28. 28.
    Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Takahashi N, Kinoshita M, Kumada H: Association of amino acid sequence in the PKR-eIf2 phosphorylation homology domain and response to interferon. Hepatology 32:1138–1144, 2000PubMedGoogle Scholar
  29. 29.
    Sarrazin, C, Berg T, Lee J-H, Ruster B, Kronenberger B, Roth WK, Zeuzem S: Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 181:432–441, 2000PubMedGoogle Scholar
  30. 30.
    Nousbaum J-B, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL, Gretch DR: Prospective characterization of fulllength hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74:9028–9038, 2000PubMedGoogle Scholar
  31. 31.
    Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, Moradpour D, Meurs EF: Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol 74:5587–5596, 2000PubMedGoogle Scholar
  32. 32.
    Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR: Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 117:1187–1197, 1999PubMedGoogle Scholar
  33. 33.
    Abid K, Quadri R, Negro F: Hepatitis C virus, the E2 envelope protein, and ?-interferon resistance. Science 287:1555, 1999Google Scholar
  34. 34.
    Cochrane A, Orr A, Shaw ML, Mills PR, McCruden EAB: The amino acid sequence of the PKR-eIF2? phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon. J Infect Dis 182:1515–1518, 2000PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Melissa D. Murphy
    • 1
    • 2
  • Hugo R. Rosen
    • 1
    • 2
  • Gail I. Marousek
    • 1
    • 2
  • Sunwen Chou
    • 1
    • 2
  1. 1.Portland VA Medical CenterMedical and Research ServicesPortlandUSA
  2. 2.Divisions of Infectious Diseases and GastroenterologyOregon Health Sciences UniversityUSA

Personalised recommendations